Company: CNTB
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001835268-25-000052
Chunk: 40

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 40
---
 and short-term investments at fair value on a recurring basis. The fair values of such assets were as follows (in thousands):Fair Value Measurements at Reporting Date UsingBalance at June 30, 2025Quoted Prices in Active Markets for Identical Assets(Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)Money market funds$9,564 $9,564 $— $— U.S. treasury bills9,928 9,928 — — U.S. government agency obligations8,917 — 8,917 — U.S. corporate debt securities3,382 — 3,382 — U.S. commercial paper6,930 — 6,930 — Foreign commercial paper1,979 — 1,979 — Total$40,700 $19,492 $21,208 $— Fair Value Measurements at Reporting Date UsingBalance at December 31, 2024Quoted Prices in Active Markets for Identical Assets (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)Money market funds$43,090 $43,090 $— $— U.S. treasury bills5,936 5,936 — — U.S. government agency obligations8,325 — 8,325 — U.S. corporate debt securities1,387 — 1,387 — U.S. commercial paper1,831 — 1,831 — Foreign commercial paper980 — 980 — Total$61,549 $49,026 $12,523 $— We have not transferred any investment securities between the three levels of the fair value hierarchy.As of June 30, 2025, short-term investments included $31.1 million of available-for-sale securities with contractual maturities of three months to one year. As of December 31, 2024, cash equivalents included $3.0 million of available-for-sale securities with contractual maturities of three months or less and short-term investments included $15.5 million of available-for-sale securities with contractual maturities of three months to one year. The money market funds as of June 30, 2025 and December 31, 2024 are included in cash and cash equivalents on the unaud